Program
icovamenib
Also written as “BMF-219”, “icovamenib 100 mg” and “icovamenib 100mg”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus, Type 1 · Leukemia, Myeloid, Acute · Carcinoma, Non-Small-Cell Lung, led by Biomea Fusion.
Furthest: phase 2, since Dec 26, 20227 company-led studies, 2 open or runningNext primary completion: Mar 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Biomea Fusion | 72 open or running | phase 2since Dec 26, 2022 | Nov 30, 2021 | Mar 2027phase 2 · NCT07502495 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 30, 2021First study: phase 1 study in Leukemia, Myeloid, AcuteFirst studyNCT05153330 · 55 enrolled · United States, Greece, Italy and more
- Nov 4, 2022Phase 1 study in Carcinoma, Non-Small-Cell LungNCT05631574 · 13 enrolled · United States, Korea, Republic of
- Dec 26, 2022Phase 2 study in Diabetes Mellitus, Type 2NCT05731544 · 443 enrolled · United States, Canada
- Nov 10, 2023Phase 2 study in Diabetes Mellitus, Type 1NCT06152042 · 37 enrolled · United States, Canada
- Oct 10, 2025Phase 1 study in Healthy VolunteerNCT07254286 · 60 enrolled · United States
- Mar 26, 20262 phase 2 studies in Diabetes Mellitus, Type 2NCT07502508, NCT07502495
Ahead
- Mar 2027Primary completion: phase 2 study in Diabetes Mellitus, Type 2NCT07502495
- Jun 2027Primary completion: phase 2 study in Diabetes Mellitus, Type 2NCT07502508
TargetBeta
KMT2A →read by rule
“An orally bioavailable, irriversible inhibitor of menin, an essential co-factor of oncogenic menin-mixed lineage leukemia (MLL; myeloid/lymphoid leukemia; KMT2A) fusion proteins, ”NCIt, by rule
Other programs on KMT2A
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| revumenibrule | Syndax Pharmaceuticals | phase 3 | 6 |
| ziftomenibrule | kura-oncology-inc | phase 3 | 6 |
| bleximenib | Johnson & Johnson | phase 3 | 4 |
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07502508Diabetes Mellitus, Type 2 · United States | 2 | Recruiting | Jun 2027 | 60 |
| NCT07502495Diabetes Mellitus, Type 2 · United States | 2 | Active, not recruiting | Mar 2027 | 64 |
| NCT07254286Healthy Volunteer · United States | 1 | Completed | Jan 14, 2026 | 60 |
| NCT06152042Diabetes Mellitus, Type 1 · United States, Canada | 2 | Completed | May 20, 2025 | 37 |
| NCT05731544Diabetes Mellitus, Type 2 · United States, Canada | 2 | Completed | Nov 18, 2024 | 443 |
| NCT05631574Carcinoma, Non-Small-Cell Lung · United States, Korea, Republic of | 1 | Terminated | Jan 15, 2025 | 13 |
| NCT05153330Leukemia, Myeloid, Acute · United States, Greece, Italy and more | 1 | Terminated | Feb 13, 2025 | 55 |
How it is read
Names in the registry
- “BMF-219”, 4 entries
- “icovamenib 100 mg”, 1 entry
- “icovamenib 100mg”, 1 entry
- “Icovamenib”, 1 entry
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 3 studies
- Diabetes Mellitus, Type 1, 1 study
- Leukemia, Myeloid, Acute, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.